DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers << Back DAREON™ 5: DLL-3 BiTE for Neuroendocrine Cancers IDENTIFIER ( ClinicalTrials.gov ) : NCT05882058 DRUG/TREATMENT : BI 764532 PHASE : 2 STATUS : Recruiting SPONSOR : Boehringer Ingelheim https://www.youtube.com/watch?v=tSN7eS8fJPw https://www.youtube.com/watch?v=nSDnIMQP2EQ DESCRIPTION: Boehringer Ingelheim is sponsoring DAREON™ -5, a phase 2 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. It is open to adults with small cell lung cancer and other neuroendocrine cancers including extra-pulmonary neuroendocrine carcinoma and large cell neuroendocrine carcinoma. The purpose of the study is to find a suitable dose of BI 764532. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Boehringer Ingelheim EMAIL: clintriage.rdg@boehringer-ingelheim.com PHONE: 1-800-243-0127 Visit this patient-friendly website for the DAREON-5 clinical trial program for more information>>>

DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) << Back DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan IDENTIFIER ( ClinicalTrials.gov ) : NCT05990738 DRUG/TREATMENT : BI 764532 (DLL3/CD3 bispecific antibody) + Topotecan PHASE : 1 STATUS : Recruiting SPONSOR : Boehringer Ingelheim DESCRIPTION: https://www.youtube.com/watch?v=YbcBQOIQU-k Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) . Recorded: June 20, 2024 Boehringer Ingelheim is sponsoring a phase 1 study, a phase 1 trial studying BI 764532 , an antibody-like molecule (DLL3/CD3 bispecific or “BiTE”) that may help the immune system fight cancer. The study is in adults with extensive stage small cell lung cancer who have previously received platinum-based chemotherapy and are eligible to receive topotecan treatment. The purpose of this study is to find out the highest dose of BI 764532 that people can tolerate when taken together with topotecan, a chemotherapy treatment called topoisomerase 1 inhibitor, that works by blocking a chemical (topoisomerase 1) that helps cancer cells repair and separate DNA when they divide. Participants get BI 764532 and topotecan as infusions into a vein. As an alternative, topotecan may also be taken orally (tablets). For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Boehringer Ingelheim EMAIL: clintriage.rdg@boehringer-ingelheim.com PHONE: 1-800-243-0127

<< Go back to the Podcast page EPISODE 31: CLINICAL TRIALS: EXPECTATIONS VS. REALITIES (PART I & II) Download a Transcript of Part 1 >> Download a Transcript of Part 2 >> ABOUT THIS EPISODE In this 2-part series, we reprise “Navigating Clinical Trials: Expectations vs Realities” with Taymeyah Al-Toubah. This was previously broadcast on August 19th, 2023, as a LACNETS monthly educational webinar. In Part 1, Taymeyah discusses clinical trial terminology, timeline, questions to ask, and misconceptions. In Part 2, Taymeyah answers questions about logistics and practical aspects of clinical trials, such as costs, response time, and follow-up. She also answers frequently asked questions about PRRT trials, including alpha trials. MEET TAYMEYAH AL-TOUBAH, MPH Taymeyah Al-Toubah is a clinical researcher, currently at Moffitt Cancer Center, who has been in the research field for 10 years. She began her career in 2013 while obtaining her bachelors degrees in biomedical sciences and psychology, working in pediatric and neonatal research at Johns Hopkins All Children’s Hospital. In 2016, she shifted her career focus to oncology, beginning with phase I trials and working in all solid tumors. She completed her Master of Public health in epidemiology in 2017 and focused her graduate thesis on neuroendocrine tumors. In 2018, she switched departments to focus exclusively on NETs. From 2018 – 2023, she was the primary NET coordinator in the GI department, managing all clinical trials while leading the GI team, managing the NET clinic coordination amongst the ancillary departments, and working on all retrospective and non-interventional NET research. She has worked on protocol development, database analysis, and manuscript writing, resulting in over 30 published manuscripts and presented her research at several national and international oncology and NET conferences, with oral abstracts at several ENETS and NANETS conferences. In April 2023, she formally transitioned to a new position as a project manager of the NET program where she will continue to mentor new coordinators, while working on protocol development and writing, manuscript writing, non-interventional clinical trials, and retrospective NET research. One of her first major projects will be to curate and develop a master database of all NET patients seen at her institution that will provide the basis for all future NET research to be published at Moffitt. She is currently on the board of one of the first NET patient advocacy groups in Florida (FLaNET Carcinoid Community), which kicked off alongside the Tampa Regional NANETS meeting in November 2022. She is an active member in NANETS on the Continuing Education and Symposium Planning committees. She plans to dedicate the remainder of her career to this disease and community. Her ultimate plan is to attend medical school, specialize in medical oncology, and continue to serve the academic NET community and patient base as a physician and clinical investigator. RESOURCES READ Glossary: Common Terms in Clinical Trials Navigating Clinical Trials: Expectations vs Realities - Slides from August 19, 2023 LACNETS Educational Event "How to Prepare for Clinical Trials" Info Sheet WATCH https://www.youtube.com/watch?v=CXW71vedhIw DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Back Other INSULINOMA upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism OTHER Belzutifan/MK-6482 in PNET + PPGL + VHL ENET STUDY: Quality of Life and Well-Being for NET Patients STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Belzutifan/MK-6482 in PNET + PPGL + VHL << Back Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) CLINICALTRIALS.GOV IDENTIFIER: NCT04924075 DRUG/TREATMENT: Oral Treatment: Belzutifan PHASE: 2 STATUS: Recruiting SPONSOR: Merck Sharp & Dohme LLC Update (May 14, 2025): Based on results from this study, the FDA approved belzutifan (Welireg) for patients with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This is the first oral therapy approved for PPGL and represents an important new treatment option. Read the FDA announcement → https://www.youtube.com/watch?v=7Hfi6VnsqCM Dr. Hendifar Discusses Belzutifan in PNET + PPGL + VHL DESCRIPTION: Merck is sponsoring a phase 2 trial for those with pheochromocytoma/paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) who have progressed in the past 12 months. Those with pNET must have experienced disease progression on or after at least 1 line of prior systemic therapy that includes an approved targeted agent such as everolimus or sunitinib. Belzutifan is a daily, oral medication currently approved for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Merck Sharp & Dohme LLC EMAIL: Trialsites@merck.com PHONE: 1-888-577-8839 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

Lu-177 DOTATATE + Cabozantanib in NETs << Back Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors CLINICALTRIALS.GOV IDENTIFIER: NCT05249114 DRUG/TREATMENT: Cabozantinib with Lu-177 DOTATATE administration IV PHASE: 1b STATUS: Recruiting SPONSORS: Providence Health & Services COLLABORATORS: Advanced Accelerator Applications SA & Exelixis https://www.youtube.com/watch?v=So_RUBe1WxM Dr. Kennecke discusses Cabozantinib with Lu-177 DOTATATE DESCRIPTION: The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib. READ: 2023 NANETS Abstract, 10/12/2023 For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATOR: Hagen Kennecke, MD, MHA Providence Health & Services CONTACT: Mary McCormick, RN EMAIL: mary.mccormick@providence.org PHONE: 503-215-9570

BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors << Back BRAVESST2: A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors IDENTIFIER ( ClinicalTrials.gov ) : NCT07129252 DRUG/TREATMENT : CRN09682 PHASE : 1/2 STATUS : Recruiting SPONSOR : Crinetics Pharmaceuticals, Inc. Download the BRAVESST2 Study Brochure here >>> DESCRIPTION: BRAVESST-2 is a Phase 1/2, first-in-human clinical trial studying a new investigational medication called CRN09682. This treatment is designed for people with metastatic or locally advanced neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), or other solid tumors that express somatostatin receptor type-2 (SST2). What is CRN09682? CRN09682 is a potential new antibody-drug conjugate (ADC) that is given by intravenous (IV) infusion. It is designed to: Recognize and attach to SST2-positive cancer cells, and Deliver a cancer-fighting drug (MMAE) directly to those cells The goal is to slow or stop tumor growth while limiting exposure to healthy cells. Why This Study Matters This study aims to understand: Safety — what side effects occur and at what doses Tolerability — how participants handle the medication How the drug behaves in the body Early signs of effectiveness in SST2-expressing tumors Because this is a first-in-human study, CRN09682 has not yet been approved by any regulatory authority. Who Can Join You may be eligible if you: Are 18 years or older Have progressive, metastatic, or locally advanced NET, NEC, or another SST2-positive solid tumor Examples include: pancreatic, lung, or GI NETs; small or large cell lung cancer; extra-pulmonary NEC; colorectal, gastric, breast, hepatocellular, nasopharyngeal carcinomas; Merkel cell carcinoma; and melanoma Crinetics_BRAVESST2_Bi-fold Par… Have not had surgery in the last 90 days Have not received prior treatment with MMAE-based therapies Your study team will confirm your full eligibility. What Participation Involves Screening period: up to 28 days IV treatment every 21 days (Cycle 1, then additional cycles) Safety follow-up: 30 days after the last dose Long-term follow-up: every 3 months Optional tumor biopsies What to Expect The study drug, lab tests, imaging, and all study procedures are provided at no cost Travel expenses may be reimbursed You may stop participation at any time For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT Name: Crinetics Clinical Trials Phone Number: 833-276-4636 Email: clinicaltrials@crinetics.com This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

Join NCF for July2026. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=iTlGH2gbmcE ABOUT Caregivers share their experiences supporting a loved one with neuroendocrine cancer, including navigating treatment decisions, managing uncertainty, balancing caregiving responsibilities, and caring for themselves along the way. Through candid conversations about challenges, lessons learned, relationships, resilience, and hope, this session offers valuable insight into the realities of the caregiving journey. Interested in hearing the patient perspective as well? View our July 2025 webinar, Living with NET: The Patient Perspective: Living with NET: The Patient Perspective . SPEAKERS ALYSE KEFELI Caregiver Alyse Kefeli lives in Rhode Island with her husband and works as an Information Technology Program Manager in the financial industry. She enjoys gardening, cooking, biking, playing pickleball, walking by the ocean, and spending time with family. She is also active in her faith and values the sense of community and support it provides. Alyse's daughter, Serra, was diagnosed with a metastatic neuroendocrine tumor (NET) that originated in the small bowel at just 32 years old. Since then, Alyse has supported Serra through two major surgeries, ongoing treatment, and the many emotional and practical challenges that come with living with NET. Along the way, she has found strength through education, faith, and connecting with other caregivers. Alyse is a member of the Neuroendocrine Cancer Foundation's monthly Caregiver Support Group, where she meets with fellow caregivers to share experiences, learn from one another, and offer mutual encouragement. She hopes that sharing her family's journey will help other caregivers feel less alone, better informed, and more hopeful as they navigate life with NET. Patient & Caregiver Journey - Sara & Quintin CYNTHIA MUELLER CROCKER Caregiver Cynthia Mueller Crocker lives in Houston with her husband, Charlie, where they gladly trade icy winters for Texas heat and humidity. After caring for and advocating for both of her aging parents, Cynthia stepped into Charlie’s NET journey with compassion and hard-earned perspective. While neuroendocrine cancer was new to her, she found education, connection, and support through LACNETS, now NCF, in 2020 and has been an active part of its weekly support groups and monthly caregiver groups ever since. Her professional background is in organization and talent development, where she has found great satisfaction in recognizing potential, identifying opportunities, and creating strategies to support the success of organizations, teams, and individuals. Charlie and Cynthia share a love of college football and happily count football season as “the best time of the year,” especially when cheering on Charlie’s Crimson Tide and Cynthia’s beloved Texas Longhorns. But their favorite seats in the bleachers is the front row cheering section as they watch their large, coast-to-coast family grow and thrive! SHANE PETERS Caregiver and Advocate Shane has been walking alongside his mother through her neuroendocrine cancer journey that started in 2020 with a diagnosis of stage four pancreatic neuroendocrine tumor that had already spread to the liver. Shane hopes to continue to give back to the NET community by sharing all he’s learned through his mother’s experiences with lanreotide, surgeries, embolizations and PRRT. Watch "The Strength of Support: the Shane and Ilka Peters Story." Watch Shane and his mother share their NET journey. Read Shane Peters' blog post 'Scan Results: To Check or Not to Check' MODERATOR: HEATHER DAVIS Director of Community Engagement Heather was a medical advocate and caregiver for 12 years for her mother, Shaunie, who was diagnosed with pancreatic neuroendocrine cancer in 2012. The efforts required to navigate and manage a rare disease, with complications of Zollinger-Ellison Syndrome, motivated Heather to shift her 20-year marketing career to patient engagement. After learning from and volunteering for LACNETS, she was pleased to join the LACNETS Team in the Fall of 2022. Heather is passionate about supporting those affected by NET. She aspires to bridge the information gap between patients, physicians and healthcare resources. Spending time with her nephews, friends & family brings her levity and joy. Watch Heather and her mother share about their experience with PRRT. T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

<< Back Immunotherapy DLL3 DAREON®-NEC-1: Obrixtamig Plus Chemotherapy vs Standard Chemotherapy in Advanced epNEC DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-7: DLL-3 for Advanced Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms CAR T CHM-2101 CAR-T cell for GI Cancers IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Cancer Vaccine Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Immune Checkpoint Inhibitor Combination Studies IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC Oncolytic Virus SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET)

Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC << Back A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab IDENTIFIER ( ClinicalTrials.gov ) : NCT05142696 DRUG/TREATMENT : LUTATHERA (Lu-177 Dotatate) + Carboplatin, Etoposide, and Atezolizumab PHASE : 1b / 2 STATUS : Recruiting SPONSOR : Novartis Pharmaceuticals DESCRIPTION: https://www.youtube.com/watch?v=0h8ye62LDT0 Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the "Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC ." Recorded: June 20, 2024 This study aims to establish a safe and well tolerated dose of [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab. The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Novartis Pharmaceuticals EMAIL: novartis.email@novartis.com PHONE: 1-888-669-6682 RELATED RESOURCES : Clinical Trials Using Lutetium Lu 177 Dotatate - NCI https://www.youtube.com/watch?v=oCHpfmQLeJM "High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer" with Aman Chauhan, MD

Join NCF for Nov2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=FiYogD5g_9A Learn about Palliative Care: what it is, what it is not, and how it may help those affected by neuroendocrine cancer. Dr. Chandana Banerjee, palliative care and hospice specialist from the City of Hope Cancer Center in Los Angeles, demystifies these topics. ABOUT CHANDANA BANERJEE, M.D., M.P.A., HMDC Chandana Banerjee, M.D., M.P.A., HMDC, is the dean, director and designated institutional official for Graduate Medical Education at City of Hope. She is also an associate professor in the Department of Supportive Care Medicine , specializing in hospice and palliative care. She developed the City of Hope Hospice & Palliative Medicine Fellowship. She also established the Cancer Pain Rotation for Kaiser Permanente Los Angeles Hospice & Palliative Medicine Fellowship, which is now part of the core curriculum for the Kaiser Permanente Southern California Hospice & Palliative Medicine fellowship program. Dr Banerjee also developed and directed the End of Life Symposium, which was first held at City of Hope in September 2019 and was endowed by Arthur Riggs, Ph.D. She is the physician lead for Schwartz Rounds at City of Hope and serves as chair on the End of Life Option Act Subcommittee. She is also a member of the Continuing Medical Education and the Ethics and Quality of Life committees. She co-founded the City of Hope Expressions of Hope initiative in partnership with Diversity, Equity and Inclusion. She is currently chair-elect of the American Academy of Hospice & Palliative Medicine's (AAHPM) Medical Aid in Dying Special Interest Group. She served as chair-elect, chair and past chair on the AAHPM Humanities and Spirituality Special Interest Group from March 2019-2022. She serves on AAHPM's Editorial Board for the publication AAHPM Quarterly and has served on the assembly's Abstract Review Board. She is a reviewer for evidence-based research articles in hospice and palliative care submitted to McMaster University in Canada. Dr. Banerjee has written and published numerous articles and book chapters and spoken at conferences nationally and internationally. She is the editor for an upcoming book by Springer Publishing's CTAR series exploring views on end-of-life care, death, burial and bereavement within different cultures and religions. She also sits on the board of directors for Compassion & Choices, an organization dedicated to end-of-life issues. Dr. Banerjee is a contributing member on the National Comprehensive Cancer Network Fatigue Panel. Her leadership activities in education include excellence in teaching, faculty development and mentoring, and curriculum and program development. Dr. Banerjee earned her undergraduate degree with an honors scholar designation from University of Connecticut. She received her master's degree in public administration from New York University and her medical degree from Saba University School of Medicine. She completed her residency in pediatrics and her fellowship in adult hospice and palliative medicine from Kaiser Permanente Los Angeles. She is also a Hospice Medical Director Certified. Dr. Banerjee was recently selected as a Health Equity Scholar into the prestigious Cambridge Health Alliance - Center for Health Equity Education & Advocacy Program’s 2021-2022 Cohort. Dr. Banerjee loves to write poetry and her first collection, "Ashen Leaves," was published in July 2020. Her second book of poems, "Neruda in Bed," was published in November 2021. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 8: PRRT (PART 1) Download a Transcript of this Episode >> Listen to Episode 9: PRRT (Part Two) with the Director of Nuclear Medicine of UCLA Health >> Listen to Episode 10: PRRT (Part Three) with Josh Mailman >> ABOUT THIS EPISODE Curious about PRRT? Wondering what a PRRT day looks like, what side effects you might experience, and what precautions you should take? NET expert and Administrative Nurse Lindy Gardner of UCLA Health answers 10 common questions about the before, during and after of PRRT. Lindy explains how to prepare for your treatment day, what to expect on the day of the treatment, and radiation precautions following PRRT including travel, vaccinations, and fertility and breastfeeding recommendations. MEET LINDY GARDNER, MSN Lindy Gardner, MSN is the lead nurse for the UCLA Peptide Receptor Radionuclide Therapy (PRRT) program. She is one of the authors of the NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Lindy earned a Bachelors of Science in Nursing from Dundee University Scotland. TOP 10 PRRT QUESTIONS 1. What can I expect on the day of PRRT infusion? What is the day like and what side effects might I experience? 2. What do I need to do to prepare for PRRT? Can I eat and drink normally the day of the treatment 3. What are the side effects after PRRT and how are they managed? 4. How concerned should I be about the radiation I’m receiving and the long-term effects? 5. What precautions should be taken, especially with small children or pets or others in the house that might be immunocompromised? 6. Does PRRT affect fertility and are there issues with pregnancy or breastfeeding after getting PRRT? 7. How should I travel home? Do I need to sit in the back seat of the car? 8. How soon can one travel after PRRT? In particular, when can one get on a plane? 9. Do I need to sleep in a separate bed and if so, how long? 10. Am I immunocompromised after my PRRT treatment? Do I need to avoid getting vaccines and am I more susceptible to bacteria and viruses? ADDITIONAL RESOURCES Read the LACNETS Blog Post "These Four Letters: PRRT" >> DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS